Pennsylvania Trust Co buys $18,318,494 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Pennsylvania Trust Co scooped up 9,719 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 311,592 shares of Merck & Co. which is valued at $18,318,494.Merck & Co. makes up approximately 1.44% of Pennsylvania Trust Co’s portfolio.

Other Hedge Funds, Including , Cypress Asset Management Inctx boosted its stake in MRK in the latest quarter, The investment management firm added 1,744 additional shares and now holds a total of 114,937 shares of Merck & Co. which is valued at $6,757,146. Merck & Co. makes up approx 1.31% of Cypress Asset Management Inctx’s portfolio.Highland Capital Management reduced its stake in MRK by selling 3,289 shares or 0.55% in the most recent quarter. The Hedge Fund company now holds 594,938 shares of MRK which is valued at $34,976,405. Merck & Co. makes up approx 2.92% of Highland Capital Management’s portfolio.Capital Analysts boosted its stake in MRK in the latest quarter, The investment management firm added 87 additional shares and now holds a total of 14,812 shares of Merck & Co. which is valued at $874,204. Merck & Co. makes up approx 0.17% of Capital Analysts’s portfolio.Pure Financial Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 244 additional shares and now holds a total of 19,541 shares of Merck & Co. which is valued at $1,163,667. Merck & Co. makes up approx 0.39% of Pure Financial Advisors’s portfolio.Gulf International Bank (uk) Ltd reduced its stake in MRK by selling 300 shares or 0.04% in the most recent quarter. The Hedge Fund company now holds 840,615 shares of MRK which is valued at $50,058,623. Merck & Co. makes up approx 0.82% of Gulf International Bank (uk) Ltd’s portfolio.

Merck & Co. opened for trading at $59 and hit $59.119 on the upside on Wednesday, eventually ending the session at $58.79, with a gain of 0.22% or 0.13 points. The heightened volatility saw the trading volume jump to 64,76,048 shares. Company has a market cap of $162,732 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.